Majority of mesothelioma (cancerous tumor affecting mesothelial cells of organs) cases come under the classification ‘pleural mesothelioma’. This is a cancer that originates in the pleura, the delicate membrane covering the lungs. Out of these, seventy five percent are diffuse malignant pleural mesethelioma. The balance is localized or benign.

Diffuse malignant pleural mesothelioma is, in most cases, caused by unprotected exposure to asbestos. The symptoms include shortness of breath and/or chest pain, loss of weight, cough, fatigue, swelling on the face, neck and arms, reduced appetite, and coughing up blood. There would be collection of fluid in the thoracic cavity. It may take from twenty to forty years or more after contact with asbestos for the symptoms to emerge. Because of the time lag, diagnosing is often difficult. Moreover, many doctors are not familiar with the disease.

Diagnostic procedure consists mostly of imaging with Computed Tomography (CT scan), Magnetic Resonance Imaging (MRI) and Position Emission Tomography (PET), and laboratory tests and analysis. Thoractomy, which means making an incision through the chest wall to look into the pleura (the membrane lining the lungs and the thoracic cavity) and pleural biopsy provide conclusive evidence.

Diffuse malignant pleural mesothelioma tumor is very aggressive and spreads fast. There are several methods to gauge the stage of the cancer. The most common is known as TNM. T is for the size of the tumor, N for the number of lymph nodules involved, and M for metastasis (spread of the cancer). There are basically four different stages. Correct grading helps the doctors to decide on the course of treatment. If the affliction is detected at an early stage, the chances of longer survival are better.

But generally the prognosis (response to treatment) is not good in diffuse malignant pleural mesothelioma cases. Surgery during Stage I may help. If detected during the later phases of the cancer the survival rate is four months to twelve months. Radiotherapy and chemotherapy do not seem to improve the survival rate. The reality is that currently there is no effective curative treatment. Research is on to find new management methods and more effectual medicines.

Pleural Mesothelioma provides detailed information on Malignant Diffuse Pleural Mesothelioma, Malignant Pleural Mesothelioma, Malignant Pleural Mesothelioma Survival Rate, Mesothelioma Pleural Brachytherapy and more. Pleural Mesothelioma is affiliated with Peritoneal Mesothelioma Lawyers.

Pleural mesothelioma has been diagnosed in 52 patients in three hospitals on Merseyside between 1955 and 1970, 60% being diagnosed from operation specimens and the rest from postmortem tissues. Necropsies eventually held on nearly half the operation cases confirmed the diagnosis, giving a necropsy rate of 70% for the series. The morbid anatomy conformed to earlier descriptions except that widespread metastases were much commoner than has usually been described.

Histological findings agreed with previous accounts of the tumour, except that, in our hands, special acid mucopolysaccharide staining was less reliable than Southgate's mucicarmine, which was of value in differential diagnosis. Association with asbestos was confirmed from industrial histories in 80% of cases, the commonest industries involved being shipbuilding and repairing in men and sackware repairing in women. Lungs of industrial mesothelioma cases showed basal asbestosis in 17% and excessive asbestos bodies in almost all the rest. Quantitative comparison of asbestos bodies in lung smears from mesothelioma cases compared with lung smears from other Merseyside adults showed much higher counts in the mesothelioma cases.

The interval from first exposure to asbestos until appearance of mesothelioma ranged between 13 and 63 years, with a mean of 42 years. We think the incidence of mesothelioma will continue to rise with the increased use of asbestos until about 40 years after adequate protective measures have been taken.